GlassScriptPhysician profile
Ricky D Patel
NPI 1992251789
$13,863.34
in general payments reported to CMS, 2019-2025
30 companies · $8,687 in 2025
The $8,687 reported for 2025 was more than what 98% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $115 · 2021: $78.69 · 2022: $1,301 · 2023: $1,013 · 2024: $2,668 · 2025: $8,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,153 · Food and Beverage: $2,588 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,600 · Travel and Lodging: $1,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,153.35 |
| Food and Beverage | $2,587.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,600.00 |
| Travel and Lodging | $1,027.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,000.96 | 2022-2025 | Da Vinci Surgical System |
| Bayer Healthcare Pharmaceuticals INC. | $1,647.87 | 2025 | |
| Bluewind Medical | $891.32 | 2024 | Revi |
| Coloplast Corp | $511.73 | 2023-2025 | Altis |
| Astellas Pharma US INC | $346.63 | 2023-2025 | Veozah, Myrbetriq |
| Baxter Healthcare | $175.44 | 2020-2021 | |
| Axonics, INC. | $151.57 | 2023 | Axonics |
| Boston Scientific Corporation | $120.26 | 2023-2024 | Solyx Sis System |
| Abbvie INC. | $106.38 | 2022-2023 | |
| Exeltis, USA INC. | $103.77 | 2022-2023 | Slynd |
| Ethicon US, LLC | $98.55 | 2023-2025 | Dermabond Prineo, Vistaseal, Stratafix |
| Sumitomo Pharma America, INC. | $85.51 | 2024-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $84.50 | 2023 | |
| Exact Sciences Corporation | $65.02 | 2024-2025 | Cologuard Collection Kit |
| Urgo Medical North America, LLC | $64.73 | 2025 | Urgok2, Urgoclean Ag |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $54.52 | 2022-2023 | Prolia, Evenity |
| Millicent US INC | $53.40 | 2024 | |
| Evofem Biosciences, INC. | $42.52 | 2025 | Solosec, Phexx, Phexxi |
| Sage Therapeutics, LLC | $37.93 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $35.96 | 2022 | |
| Mylan Pharmaceuticals INC. | $28.76 | 2022 | |
| Medline Industries LP | $26.76 | 2024 | |
| Novo Nordisk INC | $23.58 | 2023 | Wegovy |
| Hologic Sales and Service, LLC | $18.87 | 2023 | Aptima |
| Supernus Pharmaceuticals, INC. | $18.81 | 2025 | Qelbree |
| Agile Therapeutics, INC. | $18.25 | 2021 | |
| Avion Pharmaceuticals | $15.68 | 2023 | Balcoltra |
| Smith+Nephew, INC. | $14.83 | 2025 | Renasys Go V2 Home |
| Organon LLC | $10.97 | 2022 | |
| Meditrina | $8.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricky Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.